TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03470818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preparatory instructional videos (flipped classroom model)
Description: The intervention consists in the provision of preparatory instruction about the medical knowledge required to complete the task work of the upcoming simulated acute care clinical situation. The format used to convey this off-loaded educational content will be short (approximately 15 minutes) narrated video PowerPoint presentations; every relevant medical situation incorporated in the simulation case will have a dedicated video presentation.~These videos will be available to the intervention group participants on a web-based platform one week prior to the simulation session

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham video
Description: Participants in the control group will be called to watch an online video prior to the simulation activity. However, this video presentation will not have any form of information regarding the upcoming simulation case; it will be an introductory video discussing the capacities of the simulation facility. This will limit any unwanted snowball effect where discussion between research participants could lead the control group participants to inquire about a video presentation that they would not exposed to.
Study: NCT03163615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tibet Rhodiola Capsule
Description: 4 capsules, po, from admission up to 84 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 4 capsules, po, from admission up to 84 days
Study: NCT03210376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep Neuromuscular Blockade (NMB)
Description: Deep Neuromuscular Blockade (NMB) given during surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate Neuromuscular Blockade (NMB)
Description: Moderate Neuromuscular Blockade (NMB) given during surgery.
Study: NCT04376775

Intervention type: OTHER
Intervention: Transplant patient
Description: Surveys will be distributed via an email sent by transplant centres or patient's associations. A link to a secure survey platform will be given. A questionnaire will completed by patients. Patients, who agreed to fill the survey, will be offered the possibility to be contacted for a second survey over a 6 months period.
Study: NCT06607471

Intervention type: OTHER
Intervention: Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation
Description: Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.

Intervention type: OTHER
Intervention: Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation
Description: Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.

Intervention type: OTHER
Intervention: Support treatment, cardiac medical treatment, aetiology-specific treatment
Description: Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.

Intervention type: OTHER
Intervention: Support treatment, cardiac medical treatment, aetiology-specific treatment
Description: Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
Study: NCT02983266

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: InTENsity MicroCombo
Description: An electrotherapy device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InTENsity MicroCombo
Description: An electrotherapy device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InTENsity MicroCombo
Description: An electrotherapy device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InTENsity MicroCombo
Description: An electrotherapy device.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: InTENsity MicroCombo
Description: An electrotherapy device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InTENsity MicroCombo
Description: An electrotherapy device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InTENsity MicroCombo
Description: An electrotherapy device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InTENsity MicroCombo
Description: An electrotherapy device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InTENsity MicroCombo
Description: An electrotherapy device.
Study: NCT02089295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 5 mg PF-00345439 Formulation K, single dose, under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 20 mg PF-00345439 Formulation K, single dose, under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
Study: NCT02186106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Study: NCT02525822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-123 Lotion
Description: Investigational Product: IDP-123 Lotion
Study: NCT03210376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: 4 mg/Kg, intravenously as a single bolus injection after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: 70 mcg/Kg up to a total of 5 mg, intravenously slowly over a period of at least 1 minute after surgery.
Study: NCT02525822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazorac Cream, 0.1%,
Description: Comparator Product: Tazorac Cream, 0.1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Comparator Product: Vehicle Cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Lotion
Description: Comparator Product: Vehicle Lotion
Study: NCT03363945

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MDR-101
Description: Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
Study: NCT02972424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide Prefilled Syringe
Description: TPTD 20 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo as a prefilled syringe with all inactive ingredients
Study: NCT01141075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
Study: NCT03069209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cells
Description: Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
Study: NCT03476772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: Children will be randomly assigned into 2 groups of 30 patients each. They will receive caudal anesthesia using bupivacaine 0.25% 1ml/kg plus 2 ml normal saline in the control group, bupivacaine 0.25% 1ml/kg plus nalbuphine 0.1 mg/kg in 2 ml solution in the nalbuphine group.
Study: NCT03292692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OurRelationship
Description: Online intervention with coach support
Study: NCT01800305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated rhEPO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPIAO®
Study: NCT01448109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone 100mg vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion at rate of 200mg/per day for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile air filled vial
Description: the sterile air filled vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion. 2 sterile air filled vials per day for 7 days
Study: NCT01515501

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic mucosal resection (EMR)
Description: EMR uses an endoscope to take a tissue sample from the rectum. It is the same type of instrument used in a routine colonoscopy. It is hoped that this procedure will help diagnose Hirschsprung's Disease more often than by recal suction biopsy alone, which can often be unclear and result in more invasive surgery for diagnosis.
Study: NCT04345068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm Meditation Mobile App
Description: The Calm app is downloadable by participants onto their smartphone. The Calm app is used to deliver the meditation intervention to experimental group participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Podcast Mobile App
Description: The health education podcast mobile app mirrors the intervention group's app experience, but provides educational content via podcasts as an active comparator.
Study: NCT01948024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAPHRIS
Description: 10 mg BID sublingual tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: 10 mg BID sublingual tablet
Study: NCT00306475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: divalproex sodium ER
Description: divalproex sodium ER1000 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo identical in appearance to active comparator
Study: NCT02429115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentoring
Description: Six months of peer-mentoring.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentoring
Description: Six months of peer-mentoring.
Study: NCT03520036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117 low dose
Description: MT-7117 low dose QD, oral, 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117 high dose
Description: MT-7117 high dose QD, oral, 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD, oral, 16 weeks
Study: NCT03683576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB001
Description: film-coated oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB001
Description: film-coated oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB001
Description: film-coated oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: film-coated oral tablet
Study: NCT03839550

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate +SHR-1210
Description: Apatinib mesylate tablets: 250 mg, orally once a day. Take about half an hour after a meal with warm water (the daily dose should be as much as possible.~SHR-1210: 200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks. A total of 6 months of treatment,starting 4-8 weeks after radical hepatic resection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic Arterial Infusion(HAI)
Description: Twice standard HAI treatment, the first treatment was performed 4-8 weeks after radical hepatic resection, and the second treatment was given 4-8 weeks after the first treatment (the specific time interval depends on the recovery of liver function of the patient). The specific dosage regimen is 80-100 mg of epirubicin or 50 mg of epirubicin + oxaliplatin 50 mg per HAI treatment.
Study: NCT01227421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Tablets, 300 mg (one 300 mg tablet + 1 placebo tablet) with food twice daily for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Tablets, 600 mg (two 300 mg tablets) with food twice daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, (2 tablets) twice daily with food for 5 days
Study: NCT01943669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReWalk™ device
Description: Twenty one-hour ReWalk™ training sessions are scheduled for each participant over a 10-week period.
Study: NCT00764582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5% levofloxacin ophthalmic solution
Description: Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 1: 30 minutes prior to surgery~Group 2: 1 hour prior to surgery~Group 3: 2 hours prior to surgery~Group 4: 4 hours prior to surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% moxifloxacin ophthalmic solution
Description: Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 5: 30 minutes prior to surgery~Group 6: 1 hour prior to surgery~Group 7: 2 hours prior to surgery~Group 8: 4 hours prior to surgery
Study: NCT02227706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVICEL® Fibrin Sealant
Description: EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SURGICEL® Absorbable Hemostat
Description: SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
Study: NCT00266656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humatrope
Description: According to investigator's clinical practice and guided by the approved package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humatrope
Description: According to investigator's clinical practice and guided by the approved package insert
Study: NCT04571437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine metronomic combined with Letrozole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg
Description: Letrozole daily alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg
Description: Letrozole daily alone
Study: NCT01603836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone allogaft with bone marrow concentrate
Description: In forty cases, the PLF was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
Study: NCT00756795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: 5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.~Structured Interview will be conducted at baseline and post-intervention.~Patients assigned to the Intervention group will be given pedometers to obtain distance walked. In addition, patient will be taught how to keep the Exercise diary to record walking and physical activities.~All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis.
Study: NCT02408861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study: NCT03210376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Assessment
Description: Pain assessment done at about 15, 45, and 90 minutes after surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Assessment
Description: Pain assessment done at about 15, 45, and 90 minutes after surgery.
Study: NCT03695107

Intervention type: DRUG
Intervention: Nifedipine controlled released tablets
Description: lower blood pressure

Intervention type: DRUG
Intervention: Nifedipine controlled released tablets
Description: lower blood pressure
Study: NCT01797692

Intervention type: OTHER
Group type: OTHER
Intervention: geriatric assessment
Description: A single geriatric assessment with a geriatrician was proposed to patients and to control population.
Study: NCT02296268

Intervention type: BEHAVIORAL
Intervention: Aerobic Exercise Screening and Prescription Clinic
Description: Patients will be referred to the Clinic by their physiotherapist to be assessed regarding their safety and readiness to participate in aerobic training. If they are deemed to be safe and ready, an aerobic exercise prescription will be written to guide the implementation of a safe and effective training protocol. Patients deemed to be at moderate to high risk will need to be cleared for testing by a physician on the stroke service. A cardiologist will be consulted about specific concerns re cardiac status.

Intervention type: BEHAVIORAL
Intervention: Aerobic Exercise Screening and Prescription Clinic
Description: Patients will be referred to the Clinic by their physiotherapist to be assessed regarding their safety and readiness to participate in aerobic training. If they are deemed to be safe and ready, an aerobic exercise prescription will be written to guide the implementation of a safe and effective training protocol. Patients deemed to be at moderate to high risk will need to be cleared for testing by a physician on the stroke service. A cardiologist will be consulted about specific concerns re cardiac status.
Study: NCT01586390

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional treatment for ankle sprain using ankle cast
Description: Functional treatment for ankle sprain using ankle cast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle sprain treated with removable ankle support
Description: Ankle sprain functionally treated with removable and adjustable ankle support
Study: NCT01454947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS): Accountable Justifications
Description: Accountable Justifications triggered by discordant prescriptions that populate the electronic health record (EHR) note with provider's rationale for guideline exceptions (AJ).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS): Accountable Justifications
Description: Accountable Justifications triggered by discordant prescriptions that populate the electronic health record (EHR) note with provider's rationale for guideline exceptions (AJ).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS): Accountable Justifications
Description: Accountable Justifications triggered by discordant prescriptions that populate the electronic health record (EHR) note with provider's rationale for guideline exceptions (AJ).
Study: NCT04255498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.
Study: NCT01454947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS): Accountable Justifications
Description: Accountable Justifications triggered by discordant prescriptions that populate the electronic health record (EHR) note with provider's rationale for guideline exceptions (AJ).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback: Peer Comparison
Description: Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback: Peer Comparison
Description: Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback: Peer Comparison
Description: Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback: Peer Comparison
Description: Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDS Order Sets: Suggested Alternatives
Description: Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDS Order Sets: Suggested Alternatives
Description: Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDS Order Sets: Suggested Alternatives
Description: Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDS Order Sets: Suggested Alternatives
Description: Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).